Related Experiment Videos
[Current status of anticoagulants]
1Département de Médecine interne et Pneumologie, Hôpital de la Cavale Blanche, Brest. emmanuel.oger@univ-brest.fr
Insights
Direct thrombin inhibitors and low-molecular-weight heparins offer options for preventing and treating thromboembolic events. Anticoagulation duration for venous thromboembolism varies, with oral anticoagulation considered for high-risk men with ischemic heart disease.
Area of Science:
- Pharmacology and Therapeutics
- Hematology
- Cardiovascular Medicine
Background:
- Direct thrombin inhibitors, like hirudin, target thrombin's active and recognition sites, inactivating fibrin-bound thrombin.
- Low-molecular-weight heparins (LMWH) represent an alternative therapeutic strategy in anticoagulation.
Purpose of the Study:
- To outline authorized indications and treatment recommendations for direct thrombin inhibitors and LMWH in France.
- To discuss the controversial duration of anticoagulation therapy for venous thromboembolism.
- To consider the role of oral anticoagulation in primary prevention of ischemic heart disease.
Main Methods:
- Review of authorized indications for direct thrombin inhibitors (desirudin, lepirudin) and LMWH (nadroparin, tinzaparin).
- Discussion of treatment guidelines for heparin-induced thrombocytopenia and deep venous thrombosis.
- Exploration of current recommendations regarding anticoagulation duration and primary prevention strategies.
Main Results:
- Desirudin is authorized for preventing thromboembolic complications in hip or knee replacement surgery.
- Lepirudin is recommended for heparin-induced thrombocytopenia with thrombosis; danaparoid sodium for prophylaxis.
- Nadroparin and tinzaparin are effective for treating deep venous thrombosis with once-daily dosing.
Conclusions:
- Direct thrombin inhibitors and LMWH provide effective therapeutic options for various thromboembolic conditions.
- Anticoagulation duration for venous thromboembolism should be individualized based on risk factors.
- Low-intensity oral anticoagulation may be beneficial for high-risk men in primary prevention of ischemic heart disease.
Indications:
Direct inhibitors of thrombin, such as hirudin, are directed against the active site and the recognition site of thrombin. Because of their low-molecular-weight, they can inactivate thrombin bound to fibrin. Prevention of thromboembolic complications in patients undergoing primary total hip or knee replacement is now an authorized indication of desirudin in France. The recommended treatment for heparin-induced thrombocytopenia is lepirudin when there is a clinically evident thrombosis and danaparoid sodium, a mixture of anticoagulant glycosaminoglycans in an antithrombotic prophylaxis setting. LMWH: Low-molecular weight heparins are not yet authorized in France for the treatment of pulmonary embolism. However, deep venous thrombosis can be securely treated with one daily fixed dose of nadroparin or tinzaparin.
Oral Anticoagulation:
The duration of anticoagulation therapy in patients with venous thromboembolism remains controversial. Three to six months of therapy is recommended after a first episode of venous thromboembolism; the shorter regimen may be chosen when there is an identifiable and transient risk factor, and the longer when the thrombosis is idiopathic. In the context of primary prevention of ischaemic heart disease low intensity oral anticoagulation could be recommended in men at high risk.